A team of Japanese scientists reached a breakthrough breakthrough: using CRISPR – CAS9 they successfully removed a further copy of the 21 chromosome chargeable for Down syndrome in human cells.
Study, published on February 18, 2025 in Pnas Nexuspresents a precise “rescue” method, which restores the conventional expression of genes and improves cellular function in each stem cells and fibroblasts of the skin
The foremost researcher Ryotaro Hashizume from MI University and his colleagues used aiming at allele, designing CRISPR guides, which cut out only a further copy of the chromosome, ensuring that one chromosom from each parent stays intact.
They reached the removal rates of about 13 percent, which increased to about 30 percent, when DNA repair mechanisms were temporarily suppressed.
Setting specific to the alleles
Previous efforts editing the gene didn’t distinguish between three homologous copies of chromosome 21. This group, nonetheless, developed the strategy of haplotype phases and identifying the unique CRISPR goals specific to the allele.
Extracting over 15,000 sequences of recognizing the “M2 allele” specific to the duplicate, they achieved controlled removal, minimizing damage outside the goal.
Using many simultaneous CRISPR cuts marked as × 13 and temporarily dropping the genes involved in DNA repair (LIG4 and Polq), scientists significantly raised trisomic rescue efficiency.
Fluorescence hybridization in situ confirmed the removal of additional chromosome and ruled out unintentional chromosomal profits.
A positive effect on cell behavior
After removing chromosomes, each induced pluripotent stem cells and diverse fibroblasts showed restored gene expression patterns and reinforced cell phenotypes.
In particular, the treated cells showed increased activity in genes related to the event of the nervous system and reduced expression of metabolic stress genes, equalizing the advance of mitochondria function and faster proliferation.
In fibroblasts, trisomic correction increased cell growth, shortened doubles and shortened reactive oxygen forms, all key indicators of healthier cells.
The evaluation of gene ontology also confirmed that cellular behavior approached typical disomia patterns, although the outcomes for reduced genes require cautious interpretation.
Progress and restrictions
The authors of the study recognize that it stays in vitro, proof with the concept. This approach just isn’t yet able to be utilized in living organisms.
Risks persist, particularly, potential unintentional editions of other chromosomes and a technical challenge of providing precise editing machines to a mature brain cell or in vivo stem cells.
Nevertheless, Hashizume and his team emphasize that their method specific to the alleles can pave the best way for more advanced interventions focused on neurons and glial cells, potentially opening the therapy routes against trisomy 21 and other chromosomal disorders.
Ethical and clinical considerations
As a cellular intervention, these studies are a unprecedented technical feat, but ethical and safety are also increasing.
Because the double thread via CRISPR can harm the genetic material, further improvement is required to scale back the consequences outside the targets. Clinical translation would require security proof, stability of corrections and reliable delivery systems, especially within the case of nerve tissues.
Implications for the treatment of Down syndrome
Down syndrome (Trisomy 21) is probably the most common chromosomal disorder, affecting about 1 out of 700 live births.
This normally causes cognitive disorders, characteristic physical characteristics and an increased risk of health problems, akin to heart defects, leukemia and dementia related to Alzheimer’s disease.
While current treatment focuses on supporting care, akin to speech, skilled or physical, none of them concerns a genetic cause.
This approach to trisomic saving for the alleles means shifting the paradigm: as an alternative of modulating gene activity, it completely eliminates additional chromosome. In this manner, it restores the balance of genetic dosage, opening a brand new limit within the treatment of chromosomal disorders of their source.
After saying, scientists emphasize that an extended strategy to us, especially with a view to translate in vitro success into the protection and clinical lifetime of in vivo.
A breakthrough discovery
Publication in Pnas Nexus Of these Japanese research, it’s a historic technical milestone. This proves that CRISPR – CAS9 can generally eliminate an entire copy of human chromosome with a high degree of precision and measurable functional recovery in cells.
Although still on the experimental stage, work is a plan of future strategies aimed toward genetic disorders brought on by chromosomal anomal.
The next subsequent steps will include improving the accuracy of targeting, developing systems for the provision of mature tissues, conducting long -term safety assessments and moving in the moral implications of the edition of the embryo or somatic line.
For now, the study is a lighthouse of innovation, proof of the concept that in the future can transform Down syndrome and similar conditions of their genetic roots.
